Geleen, Netherlands

Isobionics B.v.


USPTO Granted Patents = 5


Trademarks = 2

Forward Citations = 1

Loading Chart...
Loading Chart...

16 inventors (with patents filed for the assignee):

goldMedal Martinus Julius Beekwilder (3 out of 4 patents)

silverMedal Georg Friedrich Lentzen (3 out of 3 patents)

bronzeMedal Hendrik Jan Bosch (3 out of 19 patents)

4.  Adèle Margaretha Maria Liduina Van Houwelingen (2 out of 2 patents)

5.  Elena Melillo (2 out of 2 patents)

6.  Hendrik Wouter Wisselink (1 out of 5 patents)

7.  Antonius Cornelis Johannes Matheus Janssen (1 out of 1 patent)

8.  Joannes Gerardus Theodorus Kierkels (1 out of 1 patent)

9.  Jihane Achkar (1 out of 1 patent)

10.  Theodorus Sonke (1 out of 6 patents)

11.  Hendrik Jan Bouwmeester (1 out of 1 patent)

12.  Karin Dautzenberg (1 out of 1 patent)

13.  Angela Gonzalez De Castro (1 out of 1 patent)

14.  Paul Alsters (1 out of 1 patent)

15.  Robert Trokowski (1 out of 1 patent)


5 patents:

Company Overview
Isobionics B.v. is a leading provider of natural flavors and fragrances. They specialize in producing high-quality, sustainable ingredients for a wide range of industries including food, beverages, cosmetics, and more. With a focus on innovation and sustainability, Isobionics is dedicated to providing its customers with environmentally friendly solutions that meet their needs.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

5 Patents

#9 in Geleen

#1,131 in Netherlands

Geleen, NL
Geleen, Netherlands
Forward Citations = 1

16 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Isobionics B.v.. Retrieved from https://idiyas.com/company/isobionics-b-v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…